Quick Facts

• May help relieve non-productive coughing.
• Supports management of dry or irritating cough.
• Intended for short-term use as needed.

---

Paxeladine 2% is a therapeutic option used for the symptomatic relief of non-productive cough, often referred to as a dry or irritating cough. It may be prescribed when persistent coughing does not produce phlegm or mucus.

The primary use of this medication is to help reduce the frequency and intensity of coughing episodes. This temporary reduction in the urge to cough can support comfort and help the patient achieve periods of rest. The therapeutic effect is generally limited to providing symptomatic management of the cough itself.

Healthcare providers may recommend this treatment for short-term management to address acute periods of irritation. Patients should consult a medical professional for advice on managing long-term or underlying respiratory conditions.

Regulatory References

1. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements

Paxeladine 2% syrup is indicated for the symptomatic treatment of dry and irritative cough (non-productive cough). It is intended for use in both adults and a specific subset of children.

---

Who Can Use Paxeladine 2%?

Population	Minimum Age/Weight Requirement
Adults	No restriction
Children	Over 30 months of age and over 15 kg

---

Who Should NOT Use Paxeladine 2%?

The cough suppressant should not be used in certain situations to prevent potential risks or complications. Contraindications include:

• Children under 30 months of age (2.5 years) or weighing less than 15 kg, due to a lack of efficacy and safety data.
• Individuals with a known allergy or hypersensitivity to oxeladine citrate (the active ingredient) or any other component of the syrup.
• Patients experiencing a productive cough (a wet cough with expectoration/phlegm), as the cough reflex serves a protective function to clear bronchial secretions.
• Pregnant or breastfeeding women; use is not recommended due to insufficient data concerning potential effects on the fetus or excretion into breast milk. Consultation with a healthcare provider is essential in these cases.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Paxeladine 2% (Oxeladin citrate), based on authoritative government regulatory sources. These statements describe restrictions and consequences of co-administration.

---

Formal Prohibitions and Restrictions

Interacting Substance/Class	Regulatory Status	Interaction Mechanism
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated (Formally Prohibited)	Pharmacodynamic risk of severe reactions, including Serotonin Syndrome.
Alcohol (Ethanol)	Precautionary Restriction	Pharmacodynamic interaction leading to enhanced Central Nervous System (CNS) depression.

---

Interactions with CNS Depressants and Gastric Agents

Co-administration with other substances that affect the CNS or alter gastric conditions requires precaution.

Interacting Substance/Class	Official Description	Restriction Type
CNS Depressants (e.g., sedatives, anxiolytics)	Additive CNS depression resulting in potentiated sedative effects.	Use with Caution
Antacids or H2-Receptor Antagonists	Pharmacokinetic interaction leading to reduced systemic absorption.	Timing Separation Required

Regulatory documentation mandates a timing separation of at least 2 hours between Paxeladine 2% and antacids/H2-receptor antagonists to mitigate the risk of reduced drug exposure. No specific enzyme- or transporter-mediated interactions are formally documented in official prescribing information.

Central Suppression via the Medullary Cough Center

Oxeladin citrate's primary action is to dampen the central cough reflex arc by modulating neuronal activity within the medullary cough center located in the brainstem . This interference with the central integration process elevates the threshold required for sensory input from the airways to trigger the reflex, resulting in a reduction of the initiation rate and force of the cough expulsion reflex.

---

Selective Sigma-1 Receptor Agonism

At the molecular level, the drug acts as a selective agonist of the Sigma-1 receptor (sigma1R), a unique protein found in central nervous system neurons. This activation is the core molecular step, initiating a cascade that leads to the stabilization and reduced excitability of the cough center neurons. The absence of opioid receptor binding ensures the mechanistic sequence remains independent of the narcotic pathway.

---

Non-Interference with Respiratory Drive

The mechanism is defined by its high selectivity, targeting the cough center while consciously avoiding modulation of the adjacent respiratory center in the brainstem. This functional selectivity ensures the central respiratory control pathways remain unmodulated by the antitussive mechanism.

The administration of Paxeladine oral solution (Oxeladin citrate) follows a standardized usage protocol.

Administration Scope

Scope Entity	Description
Route of administration:	Administration is restricted to oral use only.
Dosing schedule:	Adults: The single prescribed dose is typically 10 mg of Oxeladin citrate. The maximum total daily intake is restricted to 50 mg in divided doses.
Timing in relation to meals (if applicable):	Guidelines do not specify administration relative to food intake.
Preparation requirements (if applicable):	Accurate measurement of the liquid volume is required for each dose using the supplied measuring device.
Age-group administration rules:	Pediatric use is indicated, with dosage determined and adjusted according to the child's weight and age group. The medicine is not administered to children under 30 months of age.
Special procedural conditions:	To control the total mg intake, a mandatory 4-hour minimum interval must be observed between subsequent doses.

Instruction Classifications (High-Level)

Classification	Description
Administration method type:	Oral
Frequency pattern:	As-needed (pro re nata, PRN) dosing, strictly limited by a maximum daily total.

The protocol establishes a standardized oral route of administration and includes limits on both the single 10 mg dose and the 50 mg maximum daily intake. These constraints, which include observing a mandatory 4-hour minimum interval and applying weight-dependent dosing for children, structure the use into a precise, time-restricted sequence.

Research Evidence / Overview of Studies for Paxeladine 2%

---

Evidence for Use in Symptomatic Relief of Non-Productive Cough

The research for Paxeladine 2% (Oxeladin citrate) includes studies that explore how symptoms change over time in individuals with a dry, irritating cough associated with acute episodes. Researchers focused on short-term outcomes like cough frequency and severity, using patient-reported measures of perceived discomfort. Studies report how these symptoms evolved during the observed periods.

Study Designs: How Paxeladine Was Examined in Trials

The research base primarily involves Randomized Controlled Trials (RCTs). These studies monitored differences between Oxeladin and a placebo or compared it to other antitussives. While systematic reviews aggregate findings, the collective data often show patterns related to inconsistent findings across this category of non-opioid antitussive agents.

Evidence in Different Populations

Paxeladine was evaluated in populations primarily including adults with acute cough. Research has also explored its use in some groups of children, though data for these groups remain insufficient. The results apply only to the studied populations; applicability to individuals with chronic cough or complex comorbidities is limited and subgroup findings are uncertain.

Duration of Studies and Follow-up

The clinical research was studied for short-term follow-up durations, typically ranging from a few days to one week, consistent with the management of acute cough. Consequently, information for long-term outcomes remains limited. Research is ongoing to better understand the durability of observed short-term changes.

What is Still Uncertain About the Research for Paxeladine 2%

Scientific reviews indicate that certainty may remain low for this category, particularly regarding the clinical significance of reported outcomes. Findings were mixed across various RCTs. Evidence is limited concerning the full range of potential outcomes reflecting daily functioning, as studies focus mainly on cough scores. Comparative evidence is lacking for certain patient-relevant comparisons. Studies help show what has been observed so far, but findings describe group patterns, not personal outcomes.

Key Studies & References

1. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil (reflects the uncertainty and mixed findings for this drug category)
2. Comprehensive evidence-based review on European antitussives (used for context on acute cough trial methodology and limitations in the evidence base)
3. WHO ATC Classification Code R05DB09: Oxeladin (used to confirm regulatory classification as an 'Other cough suppressant')

Common questions about Paxeladine 2% (FAQ)

Q: How long does it typically take for Paxeladine 2% to start working?

Official information regarding the drug’s processing in the body indicates that Oxeladin citrate is designed to be well-absorbed after oral administration. Due to its pharmacokinetic profile, it is designed to provide rapid relief from coughing symptoms.

Q: What happens if I accidentally miss a dose of Paxeladine 2%?

According to regulatory guidance for as-needed (PRN) medication, if a dose is missed, it should be skipped. It is essential to wait until the next dose is due and to strictly maintain the mandatory minimum 4-hour interval between any subsequent doses. It is important not to attempt to take a double dose to compensate for the one that was missed.

Q: Is it okay to drive or operate machinery after taking Paxeladine 2%?

Regulatory documents list dizziness and sedation as rare side effects associated with this medication. Since these effects could potentially impair your ability to react, it is advised to use caution when driving or operating machinery until you know how the medication affects you.

Q: How long can I safely use Paxeladine 2% syrup for a cough?

Official regulatory summaries recommend limiting the treatment duration. Paxeladine 2% should generally be used for a maximum of 7 days. If the cough symptoms do not improve or if they worsen after this period, treatment should be discontinued and further advice sought.

Q: Can Paxeladine 2% be used for a cough caused by allergies?

Official regulatory summaries indicate that Oxeladin citrate is indicated for the symptomatic treatment of various cough origins. This includes allergic coughs, provided the cough is dry and non-productive.

Q: What should I do if my dry cough turns into a productive (wet) cough while using Paxeladine 2%?

Paxeladine 2% is strictly contraindicated for a productive, or wet, cough. If your dry cough changes and you begin to bring up phlegm or sputum, the use of this medicine should be discontinued immediately. The medicine is contraindicated because the protective cough reflex is necessary to clear secretions from the lungs.

Q: Is Paxeladine 2% less likely to cause constipation compared to codeine-based syrups?

Regulatory summaries note that Oxeladin citrate is a non-opioid antitussive, meaning it works by a different mechanism than narcotic cough suppressants like codeine. Unlike those drugs, constipation is not listed on the official side effect profile for Paxeladine 2%.

Q: Is Paxeladine 2% effective for a psychogenic or habit cough?

Official product information states that Oxeladin citrate is indicated for the symptomatic relief of various types of dry, non-productive cough, which includes those that may be psychogenic or behavioral in origin.

Q: Is Paxeladine 2% considered non-habit forming?

Yes, regulatory documentation classifies Paxeladine 2% as a non-opioid antitussive agent. There is no evidence of a risk of addiction or dependence documented in its regulatory profile.

Q: Does Paxeladine 2% work for a cough caused by post-nasal drip?

The medicine is officially indicated for the symptomatic relief of all types of dry and irritating coughs. While it is not specifically labeled for post-nasal drip, it is effective for coughs arising from general irritation of the pharynx and upper airways.

Q: Is it normal to feel a bit drowsy or dizzy after taking Paxeladine 2%?

Dizziness and sedation are recognized in the official product information as rare adverse reactions. This means they are not typically considered a normal or expected experience. If these effects occur, they should generally subside when the medication is stopped.

Q: Are there any common digestive side effects, like nausea, from Paxeladine 2%?

According to the safety information, rare adverse reactions include mild digestive disturbances. While nausea itself is not explicitly listed, it falls under the scope of these documented digestive issues.

Q: Can Paxeladine 2% cause a rash or other allergic reactions?

A rash is specifically documented as a rare adverse reaction to the medicine. The medicine is formally contraindicated, or must not be used, if a person has a known hypersensitivity (allergy) to the active ingredient, Oxeladin citrate.

Q: Why do some people say Paxeladine 2% helps clear the respiratory tract, in addition to stopping the cough?

While the primary mechanism is central (in the brainstem) to stop the cough, some regulatory documents indicate a secondary effect. They suggest that the medicine may help clear the respiratory tract by increasing and thinning bronchial secretions.

Q: Does Paxeladine 2% have any sedative properties beyond mild drowsiness?

Sedation is listed on the product label as a rare adverse reaction affecting the nervous system. The official information does not quantify the severity but classifies it as one of the central nervous system adverse effects.

Q: Why does the packaging for Paxeladine 2% mention a weight requirement for children?

The weight requirement is regulatory. Dosage for children must be carefully calculated according to their weight and age. This is because there is insufficient data to support the efficacy and safety of the medicine for children who weigh less than 15 kg or are younger than 30 months of age.

Q: Is it normal if my mouth feels dry after taking this cough syrup?

The drug may occasionally have mild anticholinergic effects, which can cause symptoms such as a dry mouth. This is a potential side effect that may be related to the drug's effect of helping to dry up respiratory secretions.

Q: Can the active ingredient in Paxeladine 2% affect blood pressure?

Regulatory information indicates that the medicine has no documented action on the cardiovascular system, suggesting it does not affect blood pressure. It is considered safe for use in patients with heart conditions.

Q: Why must I wait a minimum of 4 hours between doses of Paxeladine 2%?

The mandatory 4-hour minimum interval between doses is a requirement of the administration protocol. This rule is in place to strictly control the total daily milligram intake and ensure that the maximum authorized total daily dose is not exceeded.

The storage and disposal of Paxeladine 2% oral solution are governed by specific requirements detailed in official regulatory documentation.

Official Storage Conditions

The medicine must be stored at room temperature, specifically below 25 C (77 F), and must be protected from freezing. The product should be kept in its original container with the lid kept tightly closed to maintain its quality and prevent contamination. As with all medications, it must be stored out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposal of any unused or expired Paxeladine 2% must be carried out in accordance with local regulations. To protect the environment and public health, the oral solution should not be disposed of in household trash or poured down a sink or toilet, unless the labeling specifically instructs otherwise. The most commonly recommended disposal method is a community drug take-back program.